scPharmaceuticals Inc. (NASDAQ:SCPH – Get Free Report) was the target of a large decline in short interest in September. As of September 15th, there was short interest totalling 4,250,000 shares, a decline of 15.0% from the August 31st total of 5,000,000 shares. Based on an average daily volume of 264,000 shares, the short-interest ratio is currently 16.1 days.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of scPharmaceuticals in a report on Monday, August 19th.
Check Out Our Latest Stock Analysis on SCPH
Institutional Investors Weigh In On scPharmaceuticals
scPharmaceuticals Stock Up 4.3 %
Shares of SCPH traded up $0.19 during mid-day trading on Friday, hitting $4.61. 211,285 shares of the company’s stock were exchanged, compared to its average volume of 264,751. The company has a debt-to-equity ratio of 4.32, a current ratio of 4.84 and a quick ratio of 3.66. scPharmaceuticals has a 52 week low of $3.24 and a 52 week high of $7.15. The company has a market cap of $230.64 million, a PE ratio of -3.11 and a beta of 0.13. The company has a 50-day simple moving average of $4.95 and a 200 day simple moving average of $4.67.
scPharmaceuticals (NASDAQ:SCPH – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.44) EPS for the quarter, meeting analysts’ consensus estimates of ($0.44). The firm had revenue of $8.05 million during the quarter, compared to analysts’ expectations of $8.04 million. scPharmaceuticals had a negative net margin of 252.18% and a negative return on equity of 201.84%. On average, research analysts forecast that scPharmaceuticals will post -1.34 earnings per share for the current fiscal year.
scPharmaceuticals Company Profile
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.
Featured Articles
- Five stocks we like better than scPharmaceuticals
- What is a Low P/E Ratio and What Does it Tell Investors?
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Consumer Discretionary Stocks Explained
- MarketBeat Week in Review – 9/23 – 9/27
- What is a SEC Filing?
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for scPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for scPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.